According to the PTC's recommendations: 26/51 (51%) patients with NYHA III and 20% (10/51) NYHA II grade. The median of NT-proBNP was of 2,396 pg/ml (247–49, 280), 31/51 (61%) patients had NT-proBNP levels registered in the electronic clinical record (ECR), 3/31 (10%) patients had NT-proBNP <640 pg/ml: the average of LVEF was 31% $\pm$ 8%, 39/51 (76%) patients had LVEF levels registered in ERC, 8/51 (16%) patients had LVEF >35%. Ninety per cent of patients received ACE or ARB and 57% (29/51) received both BB and mineralcorticoid antagonists. Just 27/51 (53%) of patients were well-treated with standard care therapy (ACE/ARBs, BB and mineralcorticoid antagonists). Two per cent (1/51) of patients had GFR <30 ml/min. After the study period, 82% (42/51) of patients continued treatment with SV and patients were followed by primary care physicians.

Conclusion The results show a low adherence of prescriptions with SV according to the PTC's recommendations. The recording of the variables NT-proBNP and LVEF in the ECR could be improved.

REFERENCES AND/OR ACKNOWLEDGEMENTS

<https://doi.org/10.1093/eurheartj/ehw128>

No conflict of interest.

6ER-006 EFFECTS OF STATINS USE ON CLINICAL OUTCOMES IN PATIENTS ADMITTED WITH COMMUNITY-ACQUIRED PNEUMONIA

¹W Kabbara*, ¹H Mansour, ¹N Chamoun, ¹Y Yared, ¹M Audi, ²R Zeenny. ¹Lebanese American University, Pharmacy Practice, Byblos, Lebanon; ²American University of Beirut Medical Center, Pharmacy, Beirut, Lebanon

10.1136/ehjpharm-2019-eahpconf.603

Background Statins have shown some beneficial impact on patients with community-acquired pneumonia (CAP). This is mainly attributed to their pleiotropic effects, which include anti-inflammatory, anti-oxidative and immunomodulatory regulation.

Purpose The purpose of this study was to evaluate the effect of statins on patients admitted with CAP by assessing C-reactive protein (CRP) levels on the first and third day of hospitalisation and the length of hospital stay (LOS).

Material and methods A cross-sectional study was conducted over 12 months in a tertiary care university-affiliated medical centre. Inclusion criteria included adult patients admitted for CAP who had at least two CRP levels ordered at various days during hospitalisation. The response to antibiotic therapy was evaluated by observing a decrease in CRP level and LOS between the two studied groups. The study was performed in accordance with the Declaration of Helsinki and its later amendments and was approved by the institutional review board.

Results One-hundred and fifty-one patients were included in this study: 90 were statin users and 61 were non-users. Based on a two-tailed Pearson Chi² test, statin users had significantly more comorbid conditions such as diabetes, dyslipidaemia, hypertension and renal insufficiency, and both groups had similar percentages of congestive heart failure, chronic obstructive pulmonary disease, asthma and gastro-esophageal reflux. The severity of pneumonia (using CURB-65 criteria) was comparable between the two groups (using Pearson Chi² test). Based on a Sig 2-tailed independent sample test, no statistical significance was shown when comparing CRP levels of statin users

to non-users. On day one, the mean CRP in statin users and non-users were 17.48 and 16.45 respectively ($p=0.65$). On day three, the mean CRP decreased in both groups: 6.34 in statin users versus 6.51 in statin non-users ($p=0.858$). Similarly, the length of hospital stay was not positively impacted by the use of a statin: the mean was 8.4 days for those who were on a statin versus 8.8 days for those who were not on a statin ($p=0.298$).

Conclusion In this cross-sectional study, patients who were admitted with CAP and receiving statins did not show any difference in clinical outcomes measured by CRP levels and LOS, as compared to statin non-users.

REFERENCES AND/OR ACKNOWLEDGEMENTS

Not applicable.

No conflict of interest.

6ER-007 OFF-LABEL USE OF DALBAVANCIN IN GRAM-POSITIVE INFECTIONS: EFFECTIVENESS, SAFETY AND COST IN CLINICAL PRACTICE

¹E Chamorro-De Vega*, ¹CG Rodríguez-Gonzalez, ¹ME Rochet, ²M Valerio, ²M Olmedo, ¹A Herranz-Alonso, ²P Muñoz, ¹M Sanjurjo-Saez. ¹Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón, Pharmacy, Madrid, Spain; ²Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón, Clinical Microbiology and Infectious Diseases, Madrid, Spain

10.1136/ehjpharm-2019-eahpconf.604

Background Dalbavancin (DAL) has recently been approved to treat complicated skin and soft tissue infections. It enables treatments with a single IV administration, so it is a highly attractive option in other infections that requires long-term treatment.

Purpose To provide information on the effectiveness and safety of DAL in off-label indications under clinical practice, and its impact on reduction of length of hospital stay and hospital costs.

Material and methods Study design: prospective cohort study.

Inclusion criteria: all adult patients who received at least one dose of DAL between 1 January 2018 and 31 August 2018 in a tertiary hospital in Spain.

Effectiveness was assessed by clinical success (resolution of signs and symptoms related to bacterial infections without microbiological evidence of infection during the follow-up period). Safety was evaluated by the incidence of adverse drug events (ADE). Cost was estimated taking into account the cost of the antibiotic therapy, the cost of hospital stay and the cost of nursing visits.

Follow-up: at least 1 month after DAL therapy was discontinued.

Results A total of 19 patients received DAL for an off-label indication during the study period (60.9% males; median age 59 years). All patients received DAL as targeted therapy. The most common indications were: endocarditis ($n=6$), bacteraemia ($n=6$), osteomyelitis ($n=2$), espondilodiscitis ($n=2$), other endovascular infections ($n=2$) and pneumonia ($n=1$). These infections were mainly caused by *Staphylococcus aureus* (10 isolates), coagulase-negative *staphylococci* (six isolates) and *Enterococcus spp* (three isolates).

All patients received previous antibiotics for a median of 19 days. DAL was administered for a median of 39 days (range 15–150 days), and concomitant antimicrobial therapy was prescribed to 10 patients (53%). The administration of

DAL allowed immediate patient discharge in 73% of patients.

The overall clinical success rate of DAL was 89%. Adverse events, mainly mild in intensity, were reported in six patients. The total cost of DAL was € 62 179. Overall, DAL was estimated to reduce hospitalisation by 273 days, with an estimated overall cost reduction of € 67 466 (€ 3551 per patient).

Conclusion DAL appears to be an effective and safe therapy in several serious gram-positive infections. Its use to facilitate hospital discharge can potentially lead to cost savings.

REFERENCES AND/OR ACKNOWLEDGEMENTS

<http://dx.doi.org/10.1136/ejpharm-2018-eahpconf.160>

No conflict of interest.

6ER-008

PERSISTENCE AND REASONS FOR SWITCHING THE INITIAL ANTIRETROVIRAL TREATMENT IN A COHORT OF NAÏVE HIV-INFECTED PATIENTS

¹P Acín*, ²X Fernandez-Sala, ²M De Antonio, ²S Luque, ³E González-Colominas, ⁴H Knobel, ²S Grau. ¹Parc de Salut Mar, Farmacia Hospitalaria, Barcelona, Spain; ²Hospital del Mar, Farmacia, Barcelona, Spain; ³Hospital del Mar, Farmacia, Barcelona, Spain; ⁴Hospital del Mar, Medicina Interna, Barcelona, Spain

10.1136/ejpharm-2019-eahpconf.605

Background Current guidelines recommend starting antiretroviral treatment (ART) in all HIV-infected patients irrespective of the CD4 count.¹ Some studies have described that more than 40% of patients switch their initial ART.²

Purpose To describe initial ART in naïve patients, its persistence and the reasons leading to an ART switch.

Material and methods Retrospective observational study including all ART-naïve adult patients from January 2012 to August 2017 from our cohort of 2,060 HIV-infected patients. Patients restarting ART were excluded.

Data collected: demographic, HIV viral load (VL) and CD4⁺ count at baseline, initial ART and persistence.

Reasons for switching were classified as schedule optimisation, adverse events, toxicity prevention, drug-drug interactions, low-level viraemia, drug resistance and others.

Categorical variables, n (%); quantitative variables, mean ±SD.

The probability of switching the initial ART over time was calculated by Kaplan–Meier curves and log-rank test. Relative hazards of switching ART-naïve were calculated by Cox regression (adjusted for age, sex and CD4⁺ count).

Results During this period, 448 naïve-patients began ART: 202 (45.1%) INSTI, 137 (30.6%) PI and 109 (24.3%) NNRTI. ART-naïve was switched in 252 patients (56.3): 215 (85.3%) males, age: 39.3±10.0 years, VL≥100,000: 110 (43.8%), CD4 <200: 86 (34.4%). No differences in sex, age, baseline VL and CD4⁺ count were observed between patients with and without switching.

Kaplan–Meier showed differences in the persistence between different ART being the shortest time with the PI (p<0.001). There were statistically significant differences between ART-naïve (Hazard Ratio=2.7, p<0.001, 95% CI: 1.9 to 3.9).

Conclusion During the study period, more than 50% of patients switched their initial ART.

Differences in the persistence were observed between different ART, having the PI the shortest time.

Abstract 6ER-008 Table 1

	NNRTI n=109	INSTI n=202	PI n=137	P
Patients switching (n=252)	54 (21.4)	80 (31.8)	118 (46.8)	<0.001
Reasons, n (%)				
Schedule optimisation 92 (36.5)	3 (5.6)	21 (26.3)	68 (57.6)	<0.001
Adverse events 75 (29.8)	33 (61.1)	20 (25.0)	22 (18.6)	<0.001
Toxicity prevention 49 (19.4)	9 (16.7)	26 (32.5)	14 (11.9)	0.001
Drug-drug interactions 12 (4.8)	4 (7.4)	2 (2.5)	6 (5.1)	0.414
Low-level viraemia 9 (3.6)	3 (5.6)	3 (3.8)	3 (2.5)	0.610
Others 9 (3.6)	2 (3.7)	4 (5.0)	23 (2.5)	0.657
Drug resistance 6 (2.4)	0 (0.0)	4 (5.0)	2 (1.7)	0.141

The most common reasons for switching IP, INSTI and NNRTI were schedule optimisation, the presence of adverse events and toxicity prevention, respectively.

REFERENCES AND/OR ACKNOWLEDGEMENTS

- http://www.eacsociety.org/files/guidelines_9.0-english.pdf%0Ahttp://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html
- <http://www.ncbi.nlm.nih.gov/pubmed/11546952>

No conflict of interest.

6ER-009

PATIENT SATISFACTION AND KNOWLEDGE AFTER SWITCHING FROM EVIPLERA TO ODEFSEY

¹M Vélez-Díaz-Pallarés*, ¹T Gramage Caro, ¹MÁ Rodríguez Sagrado, ¹N Vicente Oliveros, ¹B Montero Llorente, ²A Moreno Zamora, ²MJ Vivancos Gallego, ¹Z Santander Sánchez, ¹M Salgado Del Valle, ¹T Bermejo Vicedo. ¹Hospital Ramon Y Cajal, Pharmacy, Madrid, Spain; ²Hospital Ramon Y Cajal, Infectious Diseases, Madrid, Spain

10.1136/ejpharm-2019-eahpconf.606

Background Tenofovir alafenamide (TAF) is associated with less renal and bone toxicity compared with tenofovir disoproxil (TDF) but with elevation of cholesterol levels. In our hospital, patients were automatically changed from a regimen with Eviplera (rilpivirine (RPV) +emtricitabine (FTC)+TDF) to a regimen with Odefsey (rilpivirine (RPV) +emtricitabine (FTC)+TAF). Patients were informed of the switch by the pharmacist. Patient views on the process of these medication switches have been rarely explored.

Purpose To assess the patient satisfaction and knowledge of the switch from RPV/FTC/TDF to RPV/FTC/TAF.

Material and methods Patients attending the outpatient pharmacy clinic in the months of August and September 2018 who had been previously treated with RPV/FTC/TDF and who came for the second dispensation to take RPV/FTC/TAF were included. In a face-to-face meeting with the pharmacist or by telephone, patients were asked to complete a survey. Demographic domains included gender, age, nationality of birth, education level and work status. Satisfaction and knowledge questions regarding the medication switch were assessed